This may mess up your "merger madness" bracket (kind of like Villanova is doing for the basketball brackets): Eli Lilly is not interested in a merger with Bristol-Myers Squibb, reports the Financial Times. CEO John Lechleiter told the FT that he'd rather "work to boost his company's internal development of experimental medicines alongside selective smaller-scale deals."
Drawing from S4 filings Pfizer made with the SEC, The Wall Street Journal Health Blog reports that an unnamed drug company "threatened to throw a monkey wrench" into the Pfizer/Wyeth deal. "Company X" tried to get financing from Morgan Stanley on December 16th, but by the 24th, X was out of the game. The Pfizer-Wyeth deal was announced about a month later.